Skip to main content
. 2020 Jul 22;21(15):5190. doi: 10.3390/ijms21155190

Figure 9.

Figure 9

Effects of Amb4269951 and Amb4269675 on MIA PaCa-2 xenograft tumor progression and body weight. (A) Amb4269951 (10 mg/kg, n = 5 mice), Amb4269675 (10 mg/kg, n = 5 mice), and 100% DMSO as solvent control (n = 5 mice) were injected intraperitoneally on days 0–4 and 7–11. Tumor volume measured prior to each administration of test compounds; * p < 0.05, ** p < 0.01, and *** p < 0.001 for a two-way ANOVA with Sidak’s multiple-comparisons test compared to vehicle control (DMSO). (B) Area under curve (AUC) of tumor volume in each group over 0–11 days (n = 5 mice); ** p < 0.01 and *** p < 0.001 for one-way ANOVA with Dunnett’s multiple-comparisons test compared to vehicle control (DMSO). (C) The body weight of each group was measured at each drug administration (n = 5 mice). There were no significant differences between groups throughout all treatment periods.